What the review is
Ahmed Mohamed Tawfik and seven colleagues in the Department of Oral Biology at MSA University in Giza, Egypt, have published a review of anti-USAG-1 therapy for tooth agenesis and biological tooth regeneration in Gene (article 150472, 30 October 2026; DOI 10.1016/j.gene.2026.150472; PubMed 42962738). The Elsevier full text is paywalled, so this piece is grounded in the complete author abstract as indexed at Europe PMC, not in figure-level detail. The review covers USAG-1 (SOSTDC1) biology as a regulator of tooth development, the genetics of tooth agenesis, animal studies of USAG-1 inhibition, and the ongoing clinical trials.
What it reports
The abstract restates the mechanism the field works from: USAG-1 inhibits Wnt and BMP signaling, and blocking it can reactivate arrested tooth germs and improve BMP signaling. The review’s account of the animal record matches the primary literature this site has tracked: in mice and ferrets, anti-USAG-1 treatment promoted additional or regenerated tooth-like structures and stimulated odontogenic growth, and the review reports that one antibody, #37, showed the most promise in hypodontia animal models. On the clinical side, the abstract notes that anti-USAG-1 treatment has advanced to Phase I trials in Japan to evaluate safety and pharmacokinetics. It also catalogues the agenesis genes (MSX1, PAX9, WNT10A, AXIN2, EDA and others), which is standard background rather than news.
The line the review draws
The load-bearing conclusion is in the abstract’s final sentences. The current preclinical evidence of anti-USAG-1 mediated tooth regeneration, the review states, rests mainly on animal models of congenital tooth agenesis such as hypodontia and oligodontia. Evidence supporting regeneration after acquired tooth loss due to trauma or disease is still limited, so the application of anti-USAG-1 therapy to acquired tooth loss should be viewed as a translational hypothesis rather than an experimentally validated therapeutic outcome, and studies in suitable models of acquired tooth loss are necessary. That is an author-stated boundary, not this site’s interpolation.
Where it sits in the field
The anti-USAG-1 program page already stands on the same line: the registered human work is a safety study, the efficacy claim lives in congenital-anodontia animal models, and there is no public evidence of tooth induction in a person. This review adds one thing the program record did not have: an independent, non-originator group surveying the same literature and arriving at the identical boundary. The authors are not part of the Kyoto or Toregem orbit, so this is third-party agreement rather than a restatement by the developers. Nothing in it is a new result, and no program tier moves; the current field assessment at /field/ stands.
Where we differ from the coverage
We found no press coverage of this paper to differ from. Against the broader coverage of the program, including sponsor-facing materials that present anti-USAG-1 as biological tooth replacement for people who have lost teeth, the review’s own conclusion is narrower: what is demonstrated is induction of a third dentition in congenital-agenesis animal models, and regeneration after acquired loss is a hypothesis awaiting suitable models. That is also this record’s standing position, now shared by a group with no stake in the program.
Provenance: grounded in the author abstract as indexed in the Europe PMC core record (PMID 42962738), retrieved 2026-11-01, with authors, affiliation, journal, article number, and publication date cross-checked against that record; the Elsevier full text is paywalled and was not accessible, so no figure-level numbers, group sizes, or trial counts are quoted. Method and sourcing standard at /method/.